Zep Inc. (NYSE: ZEP), a leading consumable chemical
packaged goods company that manufactures a wide variety of
high-performance maintenance and cleaning chemicals, is pleased to
announce that at its meeting today, the Board of Directors declared a
20% increase in the quarterly cash dividend from $0.05 per common share
to $0.06 cents per common share.
VANCOUVER, BC--(Marketwired - January 08, 2015) - Columbus Gold Corporation (TSX VENTURE: CGT) (OTCQX: CBGDF) ("Columbus Gold") is pleased to announce the results of comprehensive metallurgical test work from Columbus Gold's 100 % controlled Montagne d'Or Gold Deposit, Paul Isnard Project, in French Guiana.
Accenture (NYSE:ACN)’s Duck Creek property and casualty (P&C) insurance
claims software received two XCelent Awards in Celent's newly published
report titled "Claims System Vendors: North American P&C Insurance 2014 1 .”
Of the 31 core claims solutions profiled, Accenture
Duck Creek Claims took top honors in two areas: technology and
Inc. (Nasdaq:AGYS), a leading provider of innovative hospitality
software solutions and services, today announced that it has attained
Gold Certified Partner status in the Microsoft Partner Program, with a
competency in the Independent Software Vendor (ISV)/Software Solutions
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today reported results from
its randomized, open-label, multicenter Phase 2 clinical trial to
determine the safety and efficacy of eculizumab in the prevention of
antibody mediated rejection (AMR) in living-donor kidney transplant
recipients requiring desensitization.
By Russ Britt, MarketWatch
Treatment designed to help kidney patients accept new organs
Shares of Alexion Pharmaceuticals Inc. fell in after-hours trades after the drug maker said its plan to use its Soliris blood-clotting treatment to help kidney transplant patients accept their new organ didn't meet its goals in the second phase of testing.
plc (NASDAQ: ALKS) today announced positive topline results from the
12-week, randomized, double-blind, active-controlled, dose-ranging stage
of a phase 2 study of ALKS 3831, an investigational, novel, oral
atypical antipsychotic drug candidate designed to be a broad-spectrum
treatment for schizophrenia.
LAS VEGAS, NV--(Marketwired - January 07, 2015) - Allegiant Travel Company (NASDAQ: ALGT) today reported preliminary passenger traffic results for December 2014.
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.